1. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Issue 3 (3rd September 2021) Authors: Wang, Dong; Veo, Bethany; Pierce, Angela; Fosmire, Susan; Madhavan, Krishna; Balakrishnan, Ilango; Donson, Andrew; Alimova, Irina; Sullivan, Kelly D; Joshi, Molishree; Erlander, Mark; Ridinger, Maya; Foreman, Nicholas K; Venkataraman, Sujatha; Vibhakar, Rajeev Journal: Neuro-oncology Issue: Volume 24:Issue 3(2022) Page Start: 414 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Issue 1 (December 2016) Authors: Sgroi, Dennis; Chapman, Judy-Anne; Badovinac-Crnjevic, T.; Zarella, Elizabeth; Binns, Shemeica; Zhang, Yi; Schnabel, Catherine; Erlander, Mark; Pritchard, Kathleen; Han, Lei; Shepherd, Lois; Goss, Paul; Pollak, Michael Journal: Breast cancer research Issue: Volume 18:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EMBR-30. A NOVEL PLK1 INHIBITOR ONVANSERTIB EFFECTIVELY SENSITIZES GROUP 3 MEDULLOBLASTOMA TO RADIOTHERAPY. (1st June 2021) Authors: Wang, Dong; Veo, Bethany; Pierce, Angela; Foamier, Susan; Balakrishnan, Ilango; Donson, Andrew; Alimova, Irina; Erlander, Mark; Ridinger, Maya; Venkataraman, Sujatha; Vibhakar, Rajeev Journal: Neuro-oncology Issue: Volume 23(2021)Supplement 1 Page Start: i12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. Issue 1 (December 2015) Authors: Berz, David; Raymond, Victoria; Garst, Jordan; Erlander, Mark Journal: Experimental hematology & oncology Issue: Volume 5:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas. (May 2022) Authors: Affatato, Roberta; Chiappa, Michela; Guffanti, Federica; Ricci, Francesca; Formenti, Laura; Fruscio, Robert; Jaconi, Marta; Ridinger, Maya; Erlander, Mark; Damia, Giovanna Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗